An update to " The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe"

Mark Jit; Marie Josée J. Mangen; Hugues Melliez; Yazdan Yazdanpanah; Joke Bilcke; Heini Salo; William Edmunds; Philippe Beutels

doi:10.1016/j.vaccine.2010.08.060

An update to " The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe"

Mark Jit^*
, Marie Josée J. Mangen
, Hugues Melliez
, Yazdan Yazdanpanah
, Joke Bilcke
, Heini Salo
, William Edmunds
, Philippe Beutels

^*Corresponding author for this work

Research output: Contribution to journal › Letter › peer-review

38 Citations (Scopus)

Abstract

A cost-effectiveness analysis of rotavirus vaccination in Belgium, England and Wales, Finland, France and the Netherlands published in 2009 was updated based on recent studies on rotavirus burden of disease and vaccine efficacy. All the qualitative conclusions in the previous study were found to remain valid. Vaccination remains cost-effective in Finland only when using plausible tender prices.

Original language	English
Pages (from-to)	7457-7459
Number of pages	3
Journal	Vaccine
Volume	28
Issue number	47
DOIs	https://doi.org/10.1016/j.vaccine.2010.08.060
Publication status	Published - 3 Nov 2010

Bibliographical note

Funding Information:
The POLYMOD model of rotavirus vaccination was funded within the Sixth Framework Programme of the European Commission, contract number: SSP22-CT-2004-502084.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Cost-effectiveness
Rotavirus
Vaccination

Access to Document

10.1016/j.vaccine.2010.08.060

Cite this

@article{5448062acf2c447bb11b43ff27b00ae3,

title = "An update to {"} The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe{"}",

abstract = "A cost-effectiveness analysis of rotavirus vaccination in Belgium, England and Wales, Finland, France and the Netherlands published in 2009 was updated based on recent studies on rotavirus burden of disease and vaccine efficacy. All the qualitative conclusions in the previous study were found to remain valid. Vaccination remains cost-effective in Finland only when using plausible tender prices.",

keywords = "Cost-effectiveness, Rotavirus, Vaccination",

author = "Mark Jit and Mangen, \{Marie Jos{\'e}e J.\} and Hugues Melliez and Yazdan Yazdanpanah and Joke Bilcke and Heini Salo and William Edmunds and Philippe Beutels",

note = "Funding Information: The POLYMOD model of rotavirus vaccination was funded within the Sixth Framework Programme of the European Commission, contract number: SSP22-CT-2004-502084.",

year = "2010",

month = nov,

day = "3",

doi = "10.1016/j.vaccine.2010.08.060",

language = "English",

volume = "28",

pages = "7457--7459",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd.",

number = "47",

}

TY - JOUR

T1 - An update to " The cost-effectiveness of rotavirus vaccination

T2 - Comparative analyses for five European countries and transferability in Europe"

AU - Jit, Mark

AU - Mangen, Marie Josée J.

AU - Melliez, Hugues

AU - Yazdanpanah, Yazdan

AU - Bilcke, Joke

AU - Salo, Heini

AU - Edmunds, William

AU - Beutels, Philippe

N1 - Funding Information: The POLYMOD model of rotavirus vaccination was funded within the Sixth Framework Programme of the European Commission, contract number: SSP22-CT-2004-502084.

PY - 2010/11/3

Y1 - 2010/11/3

N2 - A cost-effectiveness analysis of rotavirus vaccination in Belgium, England and Wales, Finland, France and the Netherlands published in 2009 was updated based on recent studies on rotavirus burden of disease and vaccine efficacy. All the qualitative conclusions in the previous study were found to remain valid. Vaccination remains cost-effective in Finland only when using plausible tender prices.

AB - A cost-effectiveness analysis of rotavirus vaccination in Belgium, England and Wales, Finland, France and the Netherlands published in 2009 was updated based on recent studies on rotavirus burden of disease and vaccine efficacy. All the qualitative conclusions in the previous study were found to remain valid. Vaccination remains cost-effective in Finland only when using plausible tender prices.

KW - Cost-effectiveness

KW - Rotavirus

KW - Vaccination

UR - https://www.scopus.com/pages/publications/77958192364

U2 - 10.1016/j.vaccine.2010.08.060

DO - 10.1016/j.vaccine.2010.08.060

M3 - Letter

C2 - 20846529

AN - SCOPUS:77958192364

SN - 0264-410X

VL - 28

SP - 7457

EP - 7459

JO - Vaccine

JF - Vaccine

IS - 47

ER -

An update to " The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe"

Abstract

Bibliographical note

UN SDGs

Keywords

Access to Document

Other files and links

Fingerprint

Cite this